| | Study | Sample size (T/C) | Sex M/F | Age (years) range, mean | Diagnosis standards | Intervention | Control | Course of treatment | Clinical standards | Outcomes | Adverse reactions |
| | Zhang et al. 2004[29] | 94(47/47) | T: 18/16,
C: 17/13 | T: 60±8,
C: 60±8 | GMY (1999WHO-ISH) | Breviscapine injection (20 ml, ivgtt, qd) + control | Lisinopril (5-10 mg, po, tid), 25 mg, tid | 2 weeks | Guiding principles (2002) | 24UAER, SBP, DBP, B2M, TC, TG, LDL, LDH -C, Hct, PAGT, Fib | T: 2 cases of dry cough
C: 3 cases of dry cough |
| | Wei and Tan 2005[30] | 76(40/36) | T: 30/10,
C: 28/8 | T: 63.5,
C: 64.3 | GMY (1999WHO-ISH) | Breviscapine injection (20 ml, ivgtt, qd) + control | Amlodipine (5 mg, po, qd)+ Captopril (25 mg, po, tid) | 4 weeks | Guiding principles (2002) | 24 h UTP, BUN, Scr, blood B2M, Urine B2M | T: 1 showed mild facial flushing
during infusion
C: None |
| | Ren and Wu 2006[31] | 60(30/30) | T: 21/9,
C: 22/8 | T: 44-75,
C: 43-74 | CGMY (2004) | Breviscapine injection (30 ml, ivgtt, qd) + control | Captopril (25-75 mg, po, qd) or Nifedipine (20-60 mg, po, qd) | 4 weeks | Guiding principles (2002) | Clinical efficacy, 24 h UTP, BUN, Scr, | T: 2 cases of dry cough
C: 1 case of mild head inflation |
| | Zheng 2006[32] | 72(37/35) | T: 22/13,
C: 23/14 | T: 41-73,
C: 42-71 | GMY (1999WHO-ISH) | Breviscapine injection (30 ml, ivgtt, qd) + control | Captopril (25-75 mg, po, bid or tid) or Nifedipine (10-60 mg, po, bid or tid) | 4 weeks | Guiding principles (2002) | 24 h UTP, BUN, Scr, | T: 2 cases of cough
C: 1 case of mild head inflation |
| | Chen et al. 2008[33] | 57(28/29) | T: 19/9,
C: 20/9 | T: 45.6±20.3,
C: 46.4±21.1 | CGMY (2004) | Breviscapine injection (20 ml, ivgtt, qd) + control | Benazepril (no details) | 4 weeks | Guiding principles (2002) | Clinical efficacy, 24 h UTP, BUN, Scr,, Ccr | T: 2 cases of head swelling,
dizziness during infusion
C: 1 case of cough |
| | Ye 2009[34] | 75(40/35) | T: 24/16,
C: 20/15 | T: 47.3±18.2,
C: 46.9±16.1 | GMY (1999WHO-ISH) and CGMY (2005) | Breviscapine injection (5 ml, ivgtt, qd) + control | Losartan Potassium (100 mg, po, qd) | 4 weeks | Guiding principles (2002) | 24 h UTP, Scr,, Ccr, Urine B2M, SBP, DBP | T: 1 case of dizziness
C: None |
| | He and Gen 2010[35] | 168(84/84) | T: 49/35,
C: 48/36 | T: 69±11,
C: 68±11 | CGMY (2005) | Breviscapine injection (20 ml, ivgtt, qd) + control | Captopril (12.5-50 mg, po, tid) | 30 days | Guiding principles (2002) | Clinical efficacy, SBP, DBP, 24 h UTP, Scr, BUN | T: 5 cases of dry cough
C: 3 cases of dry cough |
| | Wang and Lan 2012[36] | 103(52/51) | Unclear | T: 62.4±4.8,
C: 62.4±4.8 | GMY (1999WHO-ISH) and Nephrology (Haiyan Wang) | Breviscapine injection (10 ml, ivgtt, qd) + control | Lisinopril (20 mg, po, qd) | 30 days | Guiding principles (2002) | Clinical efficacy, SBP, DBP, 24 h UTP, Scr, BUN | T: 1 case of dry cough
C: 2 cases of dry cough |
| | Liu 2012[37] | 50(26/24) | T: 12/14,
C: 10/14 | T: 55±4,
C: 53±5 | GMY (1999WHO-ISH) and CGMY (2005) | Breviscapine injection (10 ml, ivgtt, qd) + control | Benazepril (10 mg, po, bid) | 2 weeks | Guiding principles (2002) | SBP, DBP, Urinary microalbumin | Not reported |
| | Huang et al. 2013[38] | 63(33/30) | T: 24/9,
C: 19/11 | Unclear | CGMY (2004) | Breviscapine injection (20 ml, ivgtt, qd) + control | Felodipine (5 mg, po, qd)+ Aspirin (100 mg, po, qd) | 4 weeks | Guiding principles (2002) | Clinical efficacy, SBP, DBP, 24 h UTP, Scr, BUN, TC, TG, blood glucose | T: 2 cases of limb skin redness
C: None |
| | Ye 2013[39] | 48(24/24) | T: 16/8,
C: 14/10 | T: 53.0±9.3,
C: 49.0±11.6 | CGMY (2010) | Breviscapine injection (12 ml, ivgtt, qd) + control | Antihypertensive Drugs (no details) + Prostaglandin E injection (2 ml, ivgtt, qd) | 30 days | Guiding principles (2002) | Clinical efficacy, 24 h UTP, TC, TG, Scr, BUN, | Not reported |
| | Qiao 2015[40] | 158(79/79) | Unclear | T: 48.01±3.15,
C: 48.01±3.15 | GMY (1999WHO-ISH) and CGMY (2005) | Breviscapine injection (5 ml, ivgtt, qd) + control | Captopril (25-75 mg, po, tid) or Nifedipine (10-60 mg, po, tid) | 4 weeks | Guiding principles (2002) | Clinical efficacy, SBP, DBP, 224 h UTP, Scr, BUN | Not reported |
| | Zhao and Dong 2016[41] | 80(40/40) | Unclear | T: 52.5±7.1,
C: 52.5±7.1 | CGMY (2010) | Breviscapine injection (5 ml, ivgtt, qd) + control | Benazepril (5mg, po, qd) | 4 weeks | Guiding principles (2002) | Col-IV, LN, P III P, ET-1, MMP-9, NO, EILA, EISA, VOI, SBP, DBP | None |
| | Ma 2018[41] | 66(33/33) | T: 19/14,
C: 20/13 | T: 48.00±3.14,
C: 48.99±2.98 | GMY (1999WHO-ISH) and CGMY (2005) | Breviscapine injection (5 ml, ivgtt, qd) + control | Losartan Potassium (100mg, po, qd) | 4 weeks | Guiding principles (2002) | Urine B2M, SBP, DBP, 24 h UTP, Scr, Ccr | Not reported |
|
|
